RIPK2 and cancer: Most structural studies have focused on the RIPK2 KD because the functions of KD are independent of the CARD, and kinase inhibitors are well-established therapeutic agents in cancers and inflammatory diseases (Ferguson and Gray, 2018; Cohen et al., 2021; Ayala-Aguilera et al., 2022; Lee et al., 2022).